Project on

A Review on prevention and treatment of asthma in adult person

[In the partial fulfillment of the requirements for the degree of Bachelor of Pharmacy]

Submitted To

The Department of Pharmacy,

Faculty of Allied Health Sciences,

Daffodil International University

Submitted By

Student ID: 191-29-1527

Batch: 21st (D)

Department of Pharmacy,

Faculty of Allied Health Sciences,

Daffodil International University

May 2023

APPROVAL

This project paper, **A Review on the prevention and treatment of asthma in adult person**, submitted to the Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, has been accepted as satisfactory for the partial fulfillment of the requirements for the degree of Bachelor of Pharmacy and approved as to its style and contents.

BOARD OF EXAMINERS

……

Dr. Muniruddin Ahmed
Professor and Head,
Department of Pharmacy,
Faculty of Allied Health Sciences,
Daffodil International University

…… Internal Examiner 1

……. Internal Examiner 2

…… External Examiner 3

DECLARATION

I hereby declare that this project report, **A Review on the prevention and treatment of asthma in adult person**, is done by me under the supervision Most. Sumaiya Khatun Kali Lecturer, I am declaring that this Project is my original work. I also declare that neither this project nor any part thereof has been submitted elsewhere for the award of Bachelor or any degree.

Supervised by



……

Most. Sumaiya Khatun Kali

Lecturer

Department of Pharmacy

Daffodil International University.

Submitted By



……

Shahed Kyser

ID: 191-29-1527

Department of Pharmacy

Faculty of Allied Health Sciences

Daffodil International University

ACKNOWLEDGEMENT

I might want to communicate my profound applause to the All-powerful Allah who has given me the capacity to finish my undertaking work and the chance to concentrate in this subject.

I'm a lot of grateful to my honorable project supervisor Most. Sumaiya Khatun Kali Lecturer, Department of Pharmacy, Daffodil International University.

I would like to express my gentle regards to Dr. Muniruddin Ahmed, Professor and Head, Department of Pharmacy, Daffodil International University.

I also wish to offer my respect to all of the teachers of Pharmacy Department, Daffodil International University and thankful to other members for their excellent cooperation with us.

Finally, I would like to express my gratitude towards my parents and other family members for their kind cooperation and encouragement which helped me in completion of this project.

My Parents

The persons who is always encourage me in every single moment of my life. They are the inspiration of my life.

Abstract

Asthma is characterized as a lung inflammatory illness that is brought on and kept in check by an inappropriate immune response, increased airway responsiveness, and airflow restriction. In Western nations, the prevalence of asthma has rapidly increased, posing a serious threat to health. Changes in antioxidant consumption, a boost in the nutritional gap of n-6:n-3 polyunsaturated fats (PUFA), or a deficiency in vitamin D might all be to blame for the rise. In observational studies, PUFA, vitamin D, and healthy boost (vitamin E, vitamin C, beta-carotene, selenium, phenolics, and fruit) have all been associated to asthma. However, adding n-3 PUFA and antioxidant characteristics to the dietary plans of asthmatics provides little to no therapeutic impact. The usage of nutritional supplements is presently not supported by sufficient research. A small percentage of cohort studies have found a relationship between childhood asthma and mothers' prenatal consumption of certain nutrients (vitamin E, vitamin D, copper, zinc, and PUFA). Even though studies on vitamin D methods of intervention during pregnancy are still being conducted and two intervention studies indicate that dietary PUFA modification during pregnancy may be advantageous, more research is necessary to determine whether changing maternal diets during childbirth could act as a healthy, affordable health care measure to reduce the incidence of childhood asthma.

Contents

Chapter one
Introduction

1.Introduction:

Asthma, a chronic lung condition causes fluctuating airflow restriction and increased airway reactivity. Regular wheezing, shortness of breath, paroxysmal coughing, and chest pains are among the typical symptoms.[1] Symptoms intensity can range from infrequent signs to frequent exacerbations that can be fatal. A familial or personal history of allergic disease increases the risk of getting asthma. Asthma is strongly related to the allergic rhinitis allergy (eczema), allergic rhinitis (hay fever), and antibody E-mediated allergy.[19] The frequency of asthma episodes can be lowered, but not always fully prevented (LABA), with enough inhaled corticosteroid (ICS) therapy or a mixture of ICS with long-acting b-agonists. 2 Because asthma exacerbations frequently resist conventional treatment regimens, identifying at-risk individuals and having an asthma management plan in place can aid in the management of the condition and the wellness of patients.[2] Although there are efficient symptom-relieving medicines for asthma, attempts to produce disease-modifying medications have had only patchy success.[18] The complicated affectability mechanisms of asthma are reflected in the delayed pace of medication discovery. In the search for novel medications, there is still a strong inclination to interpret the illness process in one-dimensional terms and concentrate only on established asthma because this diversity is not commonly recognised.[17] The response for the most prevalent type of this illness, atopic asthma, serves as an illustration of this viewpoint because it incorporates the identity of the disease's believed principal pathogenic mechanism into its own name. It appears to be so simple that it hardly needs to be said: Asthma is brought on by atopic sensitization, which causes airway inflammation.[3]

Figure 1: Asthma Things [84]

1.1 Asthma Transmitted to Human

Exacerbations of asthma are caused by a variety of variables, including ones that are related to the environment and the host (Figure 1). Exposure to allergens, irritants, and pollutants are the main environmental causes of exacerbations, along with viral respiratory tract infections.[20] The results of viral infections are compared to children and teenagers, adults' respiratory systems and allergies are less visible. The main causes of those variations are not very fastly apparent.[4] In addition, ineffective adherence to medication is a significant risk factor that is commonly linked to the occurrence of exacerbations. Individuals with serious and unmanaged disease, elevated concentrations of type 2 (T2) inflammation, comorbidities, and limitations in antiviral activity are among the patient categories who are more at risk. For people who live in locations with higher concentrations of these environmental triggers, both inside and outside pollution continues to be a health risk for exacerbations.[21] Patients who are poor or have low incomes are at risk for exacerbations and more severe illness. Psychological conditions may also raise risk since they may affect how a person views disease management or how well they take their asthma treatment.[5] Children in modern culture may experience previously prevalent child infections less often and later in growth as compared to children with larger sibling groups because they are reared in smaller families.[22] More and more older sisters and brothers, Growing as a kid on a farm, especially due to regular exposure to the barn, the BCG vaccine, early measles and enteric diseases, less use of prescription antibiotics, and early entry into daycare settings have all been associated to a lower risk of developing atopy.[38] Initial research centered on the induction of IFN-g and other TH1-type immunity manifestations by microbes, which are known to counterregulate TH2 responses that are linked to allergens. The induction of TH1 responses by a number of other pathogenic species is thought to be a significant preventive strategy.[6]

1.2 Main Causes of Asthma

The two influenza A and B subtypes, which are the most common causes of disease, can escape immunological pressure through antigenic drift and recombination.[36] These genetic modifications result in novel subtypes, which can produce epidemic or pandemic outbreaks. 5 to 20% of the world's population contracts the influenza virus each year, although annual immunization significantly lowers related morbidity and mortality.[23] After vaccination, acute and flexible antibody cells work together to produce memory B cells and Acute and chronic plasma cells that produce antibodies. There is growing recognition of the significance of AAE and influenza as causes of significant illness. Notwithstanding questions regarding their efficacy, influenza vaccinations are strongly advised for people who have asthma.[24]

Figure 2: Causes of Asthma [94]

We conducted a preliminary search and discussed the existing understanding in the burden caused from influenza on asthma patient, the recent vaccine suggestions and thr vaccination reportage in different areas.[35] The proof relating efficacy, effectiveness, and immunogenicity, and security of the influenza vaccines, as well as the potential benefits in antiviral medications in patient with asthma in order to deal with unknowns over the avoidance and control of influenza in asthmatics. We come

to a conclusion by outlining areas of uncertainty and the need foadditional study about influenza in people with asthma.[7]

1.3 Is asthma preventable?

Given that only some populations have relatively low rates of asthma symptom prevention, which have been demonstrated by standardized international epidemiological research in both kids and adults, it is plausible to hypothesize that asthma can be prevented.[25] 5,6 These studies have identified trends of asthma syndrome severity that cannot be explained by current understanding of the causes of asthma. Nonetheless, they do offer information on risk factors, which could be used as the basis for initial preventive efforts. [26]

Figure 3: Prevention of Asthma

The wide range of possible risk factors, the inbuilt difficulty in having established cause and effect from observational association studies, the resources required to conduct controlled trials randomised controlled trials with extended follow-up further than infancy, and the rarity and frequently extremely complex nature of preventive health intervention studies have all made developing effective and feasible primary prevention strategies a challenging task.[27] The disease's variability and natural biological history make it difficult to evaluate the significance of certain risk variables or primary preventative measures that include a single intervention.[8]

1.4 Microbiological Dysbiosis in Adult Asthmatics

The burden and diversity of microbiota were found to be higher in asthmatic patients in comparison to nonasthmatic subjects in one of the initial researchers using epithelial cleanings from patients with inadequately controlled asthma.[9] The bacterial community composition was also linked to airflow obstruction and bronchial hyperresponsiveness.[10] The degree of bronchial hyperresponsiveness was inversely correlated with bacterial diversity in patients with moderate asthma, while substantial airflow obstruction was correlated with reduced bacterial diversity in patients with more severe asthma.[28] Also linked to the neutrophils and macrophages inflammation of poorly managed asthma is a decline in bacterial diversity.[11]

1.5 Clinical Reports

At third class grade of A TCM clinics in Liaoning and Beijing in 2008, almost total of the 609 young patients aged 1 from 14 who met diagnosis and inclusive parameters for recovery of asthma symptoms were managed with the acupoint treatment on "the warmest days on summer." In Liaoning, there have been 328 cases with an youth range of 6.89 to 2.82; in Hubei, there were 139 patients with just an age range of 6.55 to 2.77; and in Chengdu, there were 142 sufferers with the age range of 6.77 to 3.23. Individuals with an overall illness course of two to three years were more often men than women.[12] Age, sex, and illness course were not clearly different in the balance baseline data ($P>0.05$), indicating that they were equivalent.[29]

1.6 Prevalence of ASA sensitivity in the respiratory system

The prevalence in adult asthmatics ranges from 8% to 19%, according to research inside which oral ASA tests were employed to identify ASA sensitivity.[33] The prevalence of ASA sensitivity increases to between 30% to O%J in the subgroup of asthma patients who also have nasal polyps and sinusitis., 8 Furthermore, our early findings indicate that a similar proportion of ASA-sensitive airway obstruction disease is likely to be seen in the patient population with rhinosinusitis (polyps) and those without asthma. When identifying ASA sensitivity and analyzing prevalence data, it is important to keep in mind two practical points. It is evident that a person can have the condition and lose their ASA sensitivity, to start.[13] The sufferer may first have respiratory tract disease and later develop ASA sensitivity. A patient's tolerance to ASA is only valid at that particular time if an ASA challenge results in no reaction.[30]

1.7 From bronchiolitis to asthma, virus etiology

All wheezing disorders, from bronchiolitis to asthma, are significantly influenced by respiratory virus infections. With the help of PCR, virus detection rates have reached 100% in cases of bronchiolitis, 85-95% in kids who experience recurrent wheezing or asthma exacerbations, and 80% in cases of adult asthma exacerbations.[31] The rate of virus coinfection ranges from 10 to 40%, with young children being more susceptible. Only a small number of studies, nevertheless, have found evidence linking them to a more serious clinical course. [32] It should be highlighted that asymptomatic people may have virus detection rates with PCR that are above 35%, particularly in young children who occasionally doubt the value of virus identification.[14]

1.8 Treatment of allergic rhinitis

Over than 30% of people have allergies. Over the past 20 years, both its prevalence and that of the most prevalent allergic disorders, including such seasonal allergies (AR) or asthma, have risen in the Western world. 1 In the U.s, nearly 31 million american adults at some time in their lives, had asthma in 2002, also about 40 million has either seasonal asthma (SAR) or permanent asthma (PAR). There continues to be a demand for innovative therapy modalities even if we have several efficient therapeutic alternatives for asthma and AR. Probiotics, which have drawn a lot of scientific attention in recent years, could serve as an alternative treatment approach due to their widespread availability, lack of serious side effects, and affordable price.[96] When administered in adequate amounts, live bacteria that are called probiotics can benefit the host's health. A recent review4 discusses the medical benefits of the probiotics in a wide range of immune-middled conditions, with allergy and asthma. Animal studies5 demonstrating the benefits of probiotics in the management of the allergic problems have sparked strong interest in the uses of probiotics from the management of the allergic human illnesses.[72] A number of human studies have been conducted just on impacts of probiotics administering on the treatment of different allergic diseases. These studies are diverse and do not allow the reader to draw concrete conclusions applicable to everyday practice.[73]

1.9 Inflammation caused by a virus

Even though the guidelines have been established by which respiratory viruses like RV cause signs are unknown, there is evidence that the immune reaction to the virus plays a significant role in side effect pathogenesis. RV infections, for example, do not cause severe epithelial cell ruination, even when cold weather symptoms are present. Second, the intensity of respiratory symptoms is closely related to the infiltration of inflammatory cells as well as rises in cytokines as well as intermediaries in nasal secretions.[41] It is unknown whether these factors play a role in symptom pathogenicity or are indicators of severe disease. Third, rodent studies have shown that the morbidity of virus infection can be increased by the passive diffusion of specific T-cell subsets or clones.[44] Many airway cells and mediators are expected to play crucial parts in immune responses to viruses, despite the fact that these responses are complicated and involve several airways cells, cytokines, and other mediators. For the majority of respiratory viruses, the airway epithelial cell serves as the primary host cell. It's interesting to note that in tissue culture, both submucosal gland cells and airway cells made up of smooth muscle may contract RV. If these results are validated in vivo, it opens the door to the possibility of viral infection may directly influence muscle cell response and mucus release from the airways.[56]

Chapter two

Purpose of the study

2.1 Purpose of the study

Purpose of that study to know about following points

- Research on asthma advances our knowledge of the condition's causes, course, and most effective therapies
- We can learn more about asthma triggers, who is most at risk for developing them, and prevention strategies through research
- To learn about more variables that contribute to develop the Asthma problems
- To find out the appropial therapeutic practice for Asthma
- Review the exhibition of a patient infected with Asthma
- The main goals of this project is to get an inclusive of medical problems

Chapter three

Methodology

3.1 Materials and Procedures

This chapter talks about the research methods that were used. It is a description of the research environment. There are many variables to take into account, including the study population, the study sample, the research equipment, the technique, and the data analysis.Procedures for identified data, collected number of many correlated review paper from 2000 to 2022 review paper by using many search engines like web-based search engines, Academic bibliographic databases, PubMed, Research Gate, Google scholar and Medline.A framework research methodologies, also methods for assemblage and analyzing the data, is given by methodological review. This chapter discussion of techniques used in the investigation.

3.2 Reasarch Methodology

This is the summary of prior studies on different clinical trials as a Asthma diease treatment.

3.3 Inclusion and Exclusion Criteria

All studies in clinical trials for Asthma.

3.4 The procedure of data collection

Data is collected from various types of articles, and another portion of data is collected from the internet for the relavent disease.There are many types of reports are recorded.

3.5 Methods of Data Analysis

All of the information is get from the previous study publications which was imported and numerically coaded. A piece of the information was collected by directly reading previous research articles, while the other part came from scouring the internet for pertinent data. The activities of many treatments were recorded. All of the information gathered from prior study publications was numerically coded and imported. I was learned more by reading every composed review paper. The information acquired has been finally summarized. Data assembly, cleansing, and organization are mutual actions encompassed in data analysis techniques. The data must go through these events, which typically involve using data investigation software, in order to be prepared for business use.

Chapter four

Results & Discussion

Although there is no known cure for asthma, medicines can help reduce symptoms and allow you to continue a normal, active life. Inhalers, which are devices which enable you to inhale in medication, are the most common type of therapy. If your condition of asthma is serious, you may additionally require medications and other treatments. [39]

4.1 Inhalers

Figure 4: Inhalers

Inhalers is used:

- If the symptoms do appear, ease them. (reliever inhalers)
- Stop the emergency symtoms (preventer inhalers)
- Some people require for inhaler with those two functions (combination inhalers). [39]

4.1.1 Reliever inhalers

The vast majority of asthmatics will be given a relief inhaler. These are often blue.[40] When symptoms emerge, you address them with a relief inhaler. These should relieve your problems in a matter of minutes. Notify your doctor or a respiratory nurse if you need to take out your relief inhalation more than three times per week. They may advise further treatment, such as a preventer inhaler. Although pain reliever inhalers have minimal adverse effects, they might cause shaking or rapid breathing for a few seconds after use..[41]

4.1.2 Preventer inhalers

If you regularly need to use a pain reliever inhaler, you may also need a preventer inhaler. Every day, you take a relief inhaler to reduce the irritation and aggravation of the lungs, thereby preventing your symptoms from occurring. [42] It is essential to use it regardless of whether you are symptom-free. After taking a preventer inhaler, if symptoms persist, speak with a physician or a respiratory nurse. Inhalers for preventers contain steroids. [49]

Although they typically provide advantages, but they might also:

- a fungal infection that affects the mouth or throat (oral thrush)
- a sore throat and
- A voice that's raspy

You may help avoid these adverse effects by using a spacer, which is a hollow plastic tube connected to the inhaler, and by washing your mouth after using your inhaler. [47]

4.1.3 Combination inhalers

If pairing relief or reliever inhaler devices does not effectively manage your asthma, an inhaler that mixes the two may be required. Combination inhalers are used on a regular basis to help avoid symptoms and provide effective treatment if they occur.[46] Even though you don't have any symptoms, you should continue use it often. The adverse effects of combination inhalers are equivalent to those of relief and preventer inhalers..[44]

4.2 Pathogenesis

Exacerbations are most commonly caused by viral infections of the respiratory tract, notably those produced by human rhinovirus (RV) subtypes A and C.. Hospital stay rates for asthma flare-ups in school-aged children are correlated with the seasonal rise in RV infections from September through December and once again in the beginning of the year.[76] Adult patients with asthma experience similar peaks in hospitalization. Other respiratory conditions can also trigger acute flare-ups. Asthma is commonly linked up to death and admissions the critical care unit throughout the 2010 H1N1 An influenza problem. In addition to frequently causing wheezing in newborns and young children, respiratory syncytial virus can also cause severe asthma in adults, especially in people over 65. There have been sporadic reports of coronaviruses, adult metapneumoviruses, parainfluenza infectious agents, adenoviruses, and bocaviruses being present in asthma exacerbations.[68]

4.2.1 Bronchodilators

Adrenoceptor agonists, b2. B2- Since many years ago, adrenoceptor antagonists have been one of the more important drug groups used to treat bronchial asthma. B2-adrenoceptor agonists for inhalation that are both short- and long-acting are now readily accessible. In contrast, long-acting drugs (such as salmeterol and formoterol) should be used in combination with inhaled steroids as part of long-term treatment., it is advised that a short-act preparations be taken on a very needed basis. In the bronchodilator effects both short- and long-acting medications are consistent. Additionally, While it

has been challenging to discover solid in vivo proof, there is some indication that short-acting b2-adrenoceptor ligands have anti-inflammatory qualities. [54]

The influence of long-acting medicines on the number of flare-ups in this situation could suggest a secondary effect of this class of drugs on inflammation of the airways. Based on clinical and clinical trials with both quick- and a long-act b2-adrenoceptor agonists, it presently looks to be rather unlikely that novel bronchodilators will be developed in the near future that are more well-tolerated and more powerful. [43] Attempts have been made to imitate the actions of b2-adrenoceptor agonists, or which are predicted to relax airway smooth muscle by increasing the amount of CAM inside cells and activating potassium channels. Other compounds include nonselective phosphodiesterase inhibitors and k channel openers. These drugs were shown to be substantially less successful asthma medications than b-adrenoceptor agonists, and their usage at higher doses was limited due to severe adverse effects..[46]

4.2.2Anti-inflammatory mediation

According to theory, mediators like prostanoids, histamine, leukocytes, chemokines, cytokines, and antibodies play a key role in the beginning and ongoing development of bronchial inflammation of the airways.At the moment, inquiries are being made into all of these distinctive contributions, effects, and causes. Also a bigger knowledge about that pathways might assist disclose the way of action of categories of drugs that are already recommended and effective (like glucocorticoids), and it could also identify new avenues to help with the management of asthma. Therapy that decreases inflammation or inhibits immune system function can have a variety of impacts on inflammatory mediator synthesis, release, and consequences. [73] In theory, a more concentrated and hence more successful kind of therapy should arise from a better understanding of the regulatory mechanisms. Clinical studies are required to evaluate whether such precise approaches will produce the desired results in vivo.Since results from animal studies generally have little significance in the clinical setting, the creation of such "tailor-made" actions will be PHARMACOLOGICAL THERAPY OF ASTHMA TODAY 35s complex by differences between species. This is as results from recent clinical studies made this obvious, which will be reviewed next time.[86]

4.3 Tablets

If to use the inhaler only isn't sufficient You might additionally want to take medications to manage the signs.[50]

4.3.1 Leukotriene receptor antagonists (LTRAs)



Figure 5: LTRAs Pathway

LTRAs are the major asthma prescription drugs. They are additionally available as flour and sweetener. You take these every day to help avoid the recurrence of your symptoms. Pains and bloating are among the probable adverse reactions. [51]

4.3.2 Theophylline



Figure 6: Theophylline works

If alternative therapies fail to control your symptoms, theophylline may be prescribed. It is employed on an ongoing basis to avoid the recurrence of your symptoms. Headaches and feeling unwell are two examples of probable side effects.[52]

4.3.3 Steroid tablets

In the event that last therapies are not that successed in controlling the persons symptoms, steroid tablets are might be advised.[59]

These medications chould taken either as big term care to eliminate symptoms, which is mostly only needed when the patient have extremely lung problems also dosage forms don't really control his/her symptoms, or as an immediate therapy if you have experiencing an asthma attack on a daily base.[57]

At times, long-term or regular use of steroids in tablets can lead to side effects like as:

- a boost in hunger leading to in gaining pounds
- mood swings
- osteoporosis
- high elevated blood pressure. [55]

4.4 Injections

Figure 7: Injection

Biologic therapy are medications that are injected into some persons with severe asthma every few weeks. These may aid with symptom management. They need to be provided by such an asthma specialist and are not appropriate for all asthma sufferers. The greatest adverse effect is pain at the injection site.[56]

4.5 Surgery

A procedure termed airways thermoplasty could be considered for persons with chronic asthma. It works well, and there don't seem to be serious safety concerns. A topical anesthetic is administered to numb or put you asleep during a tracheal thermoplasty..[58] It needs you to put a flexible, thin tube

that goes through your neck and into your lung cavity. Then, in order stop rigidity and the start of asthma symptoms, the muscles around the bronchial tubes are heated. [60]

4.6 Complementary medications

A variety of alternative remedies have been promoted as viable asthma treatments, including:

- Exercising the process of breathing, like those utilizing the Buteyko's methodology and the Papworth methodology
- The herbal medication used traditionally
- acupuncture
- Ionizers are machines that charge air molecules using an electric current
- manual therapies – like chiropractic
- homeopathy
- diatry suppies [63]

Chapter five

Conclusion

5.1 Conclusion

We come to the conclusion that because asthma features are heterogeneous, alternatives to treatment must be thoroughly examined in light of the variations highlighted in international agreed articles.

Asthma patients' signs, hazards, and relapse rate should all be carefully evaluated. Any therapeutic changes need to be documented and frequently looked over by professionals..[46] If sufferers do not respond well to the primary treatment, after screening for multiple illnesses, a step up in care or alternative alternatives to therapy may be considered. [73] Followed by an exacerbation attack, a following up appointment have to be planned, also the sufferer have complete a already written asthma action plan as part of his individual asthma management education. It might be important to elevate maintenance medication dosages as a few weeks at a time, for example, during a viral illness or being around seasonal allergens. According to how you feel, the maintenance medication dosage may need to be changed on an ongoing schedule. [92] Spirometry, in addition to monitoring their own within the house employing peak airflow evaluation and avoiding activates is used to constantly assess asthma control and medication adherence for youngsters who may benefit from it. No drug, no matter how potent, can provide the entire therapeutic contribution required to control a crippling and more common chronic condition like asthma without significant, long-term adherence.[71] Adherence grows when medications are easier to use. Patients who realize their situation, have trust with their doctors, and are happy with the medication they are getting, and are free from psychological illnesses are a greater probability to follow their rehabilitation plan. [73]

Chapter six
Reference

6.1 Reference

1. Allan, K., & Devereux, G. (2011). Diet and asthma: nutrition implications from prevention to treatment. *Journal of the American Dietetic Association*, *111*(2), 258-268.

2. Castillo, J. R., Peters, S. P., & Busse, W. W. (2017). Asthma exacerbations: pathogenesis, prevention, and treatment. The Journal of Allergy and Clinical Immunology: In Practice, 5(4), 918-927.

3. Holt, P. G., & Sly, P. D. (2012). Viral infections and atopy in asthma pathogenesis: new rationales for asthma prevention and treatment. *Nature medicine*, *18*(5), 726-735.

4. Menzies-Gow, A, Busse,W. W., Castro, M., & Jackson, D. J. (2021). Prevention and treatment of asthma exacerbation in adults. The Journal of Allergy and Clinical Immunology; In Practice.9(7). 2578-2586.

5. Holgate, S. T. (2013). Mechanisms of asthma and implications for its prevention and treatment: a personal journey. *Allergy, Asthma & Immunology Research*, *5*(6), 343-347.

6. Racila, D. M., & Kline, J. N. (2005). Perspectives in asthma: molecular use of microbial products in asthma prevention and treatment. *Journal of allergy and clinical immunology*, *116*(6), 1202-1205.

7. Schwarze, J., Openshaw, P., Jha, A., Del Giacco, S. R., Firinu, D., Tsilochristou, O., ... & Skevaki, C. (2018). Influenza burden, prevention, and treatment in asthma-A scoping review by the EAACI Influenza in asthma task force. *Allergy*, *73*(6), 1151-1181.

8. Beasley, R., Semprini, A., & Mitchell, E. A. (2015). Risk factors for asthma: is prevention possible?. *The Lancet*, *386*(9998), 1075-1085.

9. Chung, K. F. (2017). Airway microbial dysbiosis in asthmatic patients: a target for prevention and treatment?. *Journal of Allergy and Clinical Immunology*, *139*(4), 1071-1081.

10. Calcaterra, V., Verduci, E., Ghezzi, M., Cena, H., Pascuzzi, M. C., Regalbuto, C., ... & Zuccotti, G. V. (2021). Pediatric obesity-related asthma: The role of nutrition and nutrients in prevention and treatment. *Nutrients*, *13*(11), 3708.

11. Wohlleben, G., & Erb, K. J. (2006). Immune stimulatory strategies for the prevention and treatment of asthma. *Current pharmaceutical design*, *12*(25), 3281-3292

12. Wen, B. L., Liu, B. Y., PENG, J., Wang, X. F., Xiang, X. X., Liu, X. F., ... & Wang, Y. (2012). Clinical research of acupoint application for "treatment of winterdisease in summer" used to prevent and treat bronchial asthma inchildren. *Journal of Traditional Chinese Medicine-English Edition*, *32*(1), 31.

13. Stevenson, D. D. (1984). Diagnosis, prevention, and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. *Journal of Allergy and Clinical Immunology*, *74*(4), 617-622.

14. Jartti, T., Bønnelykke, K., Elenius, V., & Feleszko, W. (2020, February). Role of viruses in asthma. In *Seminars in immunopathology* (Vol. 42, pp. 61-74). Springer Berlin Heidelberg.

15. Bender, B. G. (2002). Overcoming barriers to nonadherence in asthma treatment. *Journal of Allergy and Clinical Immunology*, *109*(6), S554-S559.

16. Alwarith, J., Kahleova, H., Crosby, L., Brooks, A., Brandon, L., Levin, S. M., & Barnard, N. D. (2020). The role of nutrition in asthma prevention and treatment. *Nutrition reviews*, *78*(11), 928-938.

17. Zhang, H. P., Jia, C. E., Lv, Y., Gibson, P. G., & Wang, G. (2014, July). Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis. In *Allergy & Asthma Proceedings* (Vol. 35, No. 4).

18. Kowalewicz-Kulbat, M., & Locht, C. (2021). BCG for the prevention and treatment of allergic asthma. *Vaccine*, *39*(50), 7341-7352.

19. Taylor, W. R., & Newacheck, P. W. (1992). Impact of childhood asthma on health. *Pediatrics*, *90*(5), 657-662.

20. Shahani, A. K., Korve, N., Jones, K. P., & Paynton, D. J. (1994). Towards an operational model for prevention and treatment of asthma attacks. *Journal of the Operational Research Society*, *45*(8), 916-926.

21. Paul, G., Brehm, J. M., Alcorn, J. F., Holguín, F., Aujla, S. J., & Celedón, J. C. (2012). Vitamin D and asthma. *American journal of respiratory and critical care medicine*, *185*(2), 124-132.

22. O'Byrne, P. M., & Cook, D. (1993). Is nedocromil sodium effective treatment for asthma?. *European Respiratory Journal*, *6*(1), 5-6.

23. Holgate, S. T. (2008). Pathogenesis of asthma. *Clinical & Experimental Allergy*, *38*(6), 872-897.

24. Haahtela, T., Klaukka, T., Koskela, K., Erhola, M., & Laitinen, L. A. (2001). Asthma programme in Finland: a community problem needs community solutions. *Thorax*, *56*(10), 806-814.

25. Bevis, M., & Taylor, B. (1990). What do school teachers know about asthma?. *Archives of Disease in Childhood*, *65*(6), 622-625.

26. Han, Y. Y., Blatter, J., Brehm, J. M., Forno, E., Litonjua, A. A., & Celedón, J. C. (2013). Diet and asthma: vitamins and methyl donors. *The Lancet Respiratory Medicine*, *1*(10), 813-822.

27. Martinez, F. D. (1999). Recognizing early asthma. *Allergy*, *54*, 24-28.

28. Cevhertas, L., Ogulur, I., Maurer, D. J., Burla, D., Ding, M., Jansen, K., ... & Akdis, C. A. (2020). Advances and recent developments in asthma in 2020. *Allergy*, *75*(12), 3124-3146.

29. Jartti, T., Bønnelykke, K., Elenius, V., & Feleszko, W. (2020, February). Role of viruses in asthma. In *Seminars in immunopathology* (Vol. 42, pp. 61-74). Springer Berlin Heidelberg.

30. Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., ... & Zar, H. J. (2008). Global strategy for asthma management and prevention: GINA executive summary. *European Respiratory Journal*, *31*(1), 143-178.

31. Guilbert, T. W., Morgan, W. J., Krawiec, M., Lemanske Jr, R. F., Sorkness, C., Szefler, S. J., ... & Martinez, F. D. (2004). The Prevention of Early Asthma in Kids study: design, rationale and methods for the Childhood Asthma Research and Education network. *Controlled clinical trials*, *25*(3), 286-310.

32. Fuhlbrigge, A. L., Adams, R. J., Guilbert, T. W., Grant, E., Lozano, P., Janson, S. L., ... & Weiss, S. T. (2002). The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. *American journal of respiratory and critical care medicine*, *166*(8), 1044-1049.

33. Gern, J. E., & Pavord, I. D. (2023). Challenges and Opportunities in Asthma Prevention and Treatment. *The Journal of Allergy and Clinical Immunology: In Practice*, *11*(3), 748-749.

34. Murray, C. S., Jackson, D. J., & Teague, W. G. (2021). Prevention and outpatient treatment of asthma exacerbations in children. *The Journal of Allergy and Clinical Immunology: In Practice*, *9*(7), 2567-2576.

35. Riedl, M. A., & Nel, A. E. (2008). Importance of oxidative stress in the pathogenesis and treatment of asthma. *Current opinion in allergy and clinical immunology*, *8*(1), 49-56.

36. Sykes, A., & Johnston, S. L. (2008). Etiology of asthma exacerbations. *Journal of allergy and clinical immunology*, *122*(4), 685-688.

37. Han, Y. Y., Forno, E., Holguin, F., & Celedón, J. C. (2015). Diet and asthma: an update. *Current opinion in allergy and clinical immunology*, *15*(4), 369.

38. Camargo Jr, C. A., Rachelefsky, G., & Schatz, M. (2009). Managing asthma exacerbations in the emergency department: summary of the National Asthma Education and Prevention Program Expert Panel Report 3 guidelines for the management of asthma exacerbations. *Proceedings of the American Thoracic Society*, *6*(4), 357-366.

39. Yu, J., Jang, S. O., Kim, B. J., Song, Y. H., Kwon, J. W., Kang, M. J., ... & Hong, S. J. (2010). The effects of Lactobacillus rhamnosus on the prevention of asthma in a murine model. *Allergy, asthma & immunology research*, *2*(3), 199-205.

40. Campbell, I. A., Douglas, J. G., Francis, R. M., Prescott, R. J., & Reid, D. M. (2004). Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. *Thorax*, *59*(9), 761-768.

41. Ford, E. S. (2005). The epidemiology of obesity and asthma. *Journal of allergy and clinical immunology*, *115*(5), 897-909.

42. Bustos, G. J., Bustos, D., Bustos, G. J., & Romero, O. (1995). Prevention of asthma with ketotifen in preasthmatic children: a three-year follow-up study. *Clinical & Experimental Allergy*, *25*(6), 568-573.

43. Bacharier, L. B., Boner, A., Carlsen, K. H., Eigenmann, P. A., Frischer, T., Götz, M., ... & European Pediatric Asthma Group. (2008). Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. *Allergy*, *63*(1), 5-34.

44. Humbert, M., Holgate, S., Boulet, L. P., & Bousquet, J. (2007). Asthma control or severity: that is the question. *Allergy*, *62*(2), 95-101.

45. Tanno, L. K., Haahtela, T., Calderon, M. A., Cruz, A., Demoly, P., of Allergy, E. A., ... & World Allergy Organization. (2017). Implementation gaps for asthma prevention and control. *Respiratory Medicine*, *130*, 13-19.

46. Jacobsen, L. (2001). Preventive aspects of immunotherapy: prevention for children at risk of developing asthma. *Annals of Allergy, Asthma & Immunology*, *87*(1), 43-46.

47. Martinez, F. D. (2007). Asthma treatment and asthma prevention: a tale of 2 parallel pathways. *Journal of allergy and clinical immunology*, *119*(1), 30-33.

48. Royce, S. G., & Tang, M. L. (2009). The effects of current therapies on airway remodeling in asthma and new possibilities for treatment and prevention. *Current Molecular Pharmacology*, *2*(2), 169-181.

49. Bergeron, C., Tulic, M. K., & Hamid, Q. (2010). Airway remodelling in asthma: from benchside to clinical practice. *Canadian respiratory journal*, *17*(4), e85-e93.

50. Cowie, R. L., Revitt, S. G., Underwood, M. F., & Field, S. K. (1997). The effect of a peak flow-based action plan in the prevention of exacerbations of asthma. *Chest*, *112*(6), 1534-1538.

51. Suissa, S., Ernst, P., Benayoun, S., Baltzan, M., & Cai, B. (2000). Low-dose inhaled corticosteroids and the prevention of death from asthma. *New England Journal of Medicine*, *343*(5), 332-336.

52. Niggemann, B., Jacobsen, L., Dreborg, S., Ferdousi, H. A., Halken, S., Høst, A., ... & PAT Investigator Group. (2006). Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. *Allergy*, *61*(7), 855-859.

53. Aalbers, R., Vogelmeier, C., & Kuna, P. (2016). Achieving asthma control with ICS/LABA: a review of strategies for asthma management and prevention. *Respiratory Medicine*, *111*, 1-7.

54. Hay, I. F. C., & Higenbottam, T. W. (1987). Has the management of asthma improved?. *The Lancet*, *330*(8559), 609-611.

55. Corren, J., Manning, B. E., Thompson, S. F., Hennessy, S., & Strom, B. L. (2004). Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. *Journal of Allergy and Clinical Immunology*, *113*(3), 415-419.

56. Kuipers, H., & Lambrecht, B. N. (2005). Modification of dendritic cell function as a tool to prevent and treat allergic asthma. *Vaccine*, *23*(37), 4577-4588.

57. Sullivan, S., Elixhauser, A., Buist, A. S., Luce, B. R., Eisenberg, J., & Weiss, K. B. (1996). National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care. *Am J Respir Crit Care Med*, *154*(3 Pt 2), S84-95.

58. Guibas, G. V., Makris, M., & Papadopoulos, N. G. (2012). Acute asthma exacerbations in childhood: risk factors, prevention and treatment. *Expert review of respiratory medicine*, *6*(6), 629-638.

59. Morjaria, J. B., Caruso, M., Emma, R., Russo, C., & Polosa, R. (2018). Treatment of allergic rhinitis as a strategy for preventing asthma. *Current allergy and asthma reports*, *18*, 1-9.

60. Weinberger, M. (2004). Respiratory infections and asthma: current treatment strategies. *Drug discovery today*, *9*(19), 831-837.

61. Jacobsen, L., Niggemann, B., Dreborg, S., Ferdousi, H. A., Halken, S., Høst, A., ... & PAT investigator group). (2007). Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. *Allergy*, *62*(8), 943-948.

62. Spergel, J. M. (2010). From atopic dermatitis to asthma: the atopic march. *Annals of allergy, asthma & immunology*, *105*(2), 99-106.

63. Lange, N. E., Litonjua, A., Hawrylowicz, C. M., & Weiss, S. (2009). Vitamin D, the immune system and asthma. *Expert review of clinical immunology*, *5*(6), 693-702.

64. Rabe, K. F., & Schmidt, D. T. (2001). Pharmacological treatment of asthma today. *European Respiratory Journal*, *18*(34 suppl), 34s-40s.

65. D'Amato, G., Vitale, C., Lanza, M., Sanduzzi, A., Molino, A., Mormile, M., ... & D'Amato, M. (2016). Near fatal asthma: treatment and prevention. *European annals of allergy and clinical immunology*, *48*(4), 116-122.

66. Smits, H. H., Hiemstra, P. S., Da Costa, C. P., Ege, M., Edwards, M., Garn, H., ... & Taube, C. (2016). Microbes and asthma: opportunities for intervention. *Journal of Allergy and Clinical Immunology*, *137*(3), 690-697.

67. Blais, L., Suissa, S., Boivin, J. F., & Ernst, P. (1998). First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma. *Thorax*, *53*(12), 1025-1029.

68. Haahtela, T., Alenius, H., Lehtimäki, J., Sinkkonen, A., Fyhrquist, N., Hyöty, H., ... & Mäkelä, M. J. (2021). Immunological resilience and biodiversity for prevention of allergic diseases and asthma. *Allergy*, *76*(12), 3613-3626.

69. Lemanske Jr, R. F., & Busse, W. W. (2010). Asthma: clinical expression and molecular mechanisms. *Journal of allergy and clinical immunology*, *125*(2), S95-S102.

70. Suissa, S., Ernst, P., & Kezouh, A. (2002). Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. *Thorax*, *57*(10), 880-884.

71. Spector, S. L. (1993). Update on exercise-induced asthma. *Annals of allergy*, *71*(6), 571-577.

72. Williams, D. R., Sternthal, M., & Wright, R. J. (2009). Social determinants: taking the social context of asthma seriously. *Pediatrics*, *123*(Supplement_3), S174-S184.

73. Barlan, I. B., Bahceciler, N., Akdis, M., & Akdis, C. A. (2005). Role of bacillus Calmette–Guérin as an immunomodulator for the prevention and treatment of allergy and asthma. *Current opinion in allergy and clinical immunology*, *5*(6), 552-557.

74. Bochenek, G., Bánska, K., Szabó, Z., Nizankowska, E., & Szczeklik, A. (2002). Diagnosis, prevention and treatment of aspirin-induced asthma and rhinitis. *Current Drug Targets-Inflammation & Allergy*, *1*(1), 1-11.

75. Rosenthal, L. A., Avila, P. C., Heymann, P. W., Martin, R. J., Miller, E. K., Papadopoulos, N. G., ... & Infections and Asthma Committee. (2010). Viral respiratory tract infections and asthma: the course ahead. *Journal of allergy and clinical immunology*, *125*(6), 1212-1217.

76. Zhou, X., & Hong, J. (2018). Pediatric asthma management in China: current and future challenges. *Pediatric Drugs*, *20*, 105-110.

77. Rowe, B. H., Spooner, C., Ducharme, F., Bretzlaff, J., Bota, G., & Cochrane Airways Group. (1996). Corticosteroids for preventing relapse following acute exacerbations of asthma. *Cochrane Database of Systematic Reviews*, *2008*(4).

78. Brożek, J. L., Bousquet, J., Baena-Cagnani, C. E., Bonini, S., Canonica, G. W., Casale, T. B., ... & Schünemann, H. J. (2010). Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. *Journal of Allergy and Clinical Immunology*, *126*(3), 466-476.

79. Gibson, P. G., Henry, R. L., Vimpani, G. V., & Halliday, J. (1995). Asthma knowledge, attitudes, and quality of life in adolescents. *Archives of disease in childhood*, *73*(4), 321-326.

80. Jackson, D. J., Sykes, A., Mallia, P., & Johnston, S. L. (2011). Asthma exacerbations: origin, effect, and prevention. *Journal of Allergy and Clinical Immunology*, *128*(6), 1165-1174.

81. Nieto, A., Wahn, U., Bufe, A., Eigenmann, P., Halken, S., Hedlin, G., ... & Mazon, A. (2014). Allergy and asthma prevention 2014. *Pediatric Allergy and Immunology*, *25*(6), 516-533.

82. Hand, C. H., & Bradley, C. (1996). Health beliefs of adults with asthma: toward an understanding of the difference between symptomatic and preventive use of inhaler treatment. *Journal of Asthma*, *33*(5), 331-338.

83. Vignola, A. M., Mirabella, F., Costanzo, G., Di Giorgi, R., Gjomarkaj, M., Bellia, V., & Bonsignore, G. (2003). Airway remodeling in asthma. *Chest*, *123*(3), 417S-422S.

84. Johnson, L. H., Chambers, P., & Dexheimer, J. W. (2016). Asthma-related emergency department use: current perspectives. *Open access emergency medicine: OAEM*, *8*, 47.

85. Griffiths, C., Drews, S. J., & Marchant, D. J. (2017). Respiratory syncytial virus: infection, detection, and new options for prevention and treatment. *Clinical microbiology reviews*, *30*(1), 277-319.

86. Cressy, D. S., & DeBoisblanc, B. P. (1998). Diagnosis and management of asthma: a summary of the National Asthma Education and Prevention Program guidelines. National Institutes of Health. *The Journal of the Louisiana State Medical Society: official organ of the Louisiana State Medical Society*, *150*(12), 611-617.

87. Papi, A., Blasi, F., Canonica, G. W., Morandi, L., Richeldi, L., & Rossi, A. (2020). Treatment strategies for asthma: reshaping the concept of asthma management. *Allergy, Asthma & Clinical Immunology*, *16*, 1-11.

88. Karmaus, W., Ziyab, A. H., Everson, T., & Holloway, J. W. (2013). Epigenetic mechanisms and models in the origins of asthma. *Current opinion in allergy and clinical immunology*, *13*(1), 63.

89. Vliagoftis, H., Kouranos, V. D., Betsi, G. I., & Falagas, M. E. (2008). Probiotics for the treatment of allergic rhinitis and asthma: systematic review of randomized controlled trials. *Annals of Allergy, Asthma & Immunology*, *101*(6), 570-579.

90. Meirlaen, L., Levy, E. I., & Vandenplas, Y. (2021). Prevention and management with pro-, pre and synbiotics in children with asthma and allergic rhinitis: a narrative review. *Nutrients*, *13*(3), 934.

91. Vuillermin, P. J., Brennan, S. L., Robertson, C. F., Carlin, J. B., Prior, M., Jenner, B. M., & South, M. (2010). Anxiety is more common in children with asthma. *Archives of disease in childhood*, *95*(8), 624-629.

92. Blais, L., Ernst, P., Boivin, J. F., & Suissa, S. (1998). Inhaled corticosteroids and the prevention of readmission to hospital for asthma. *American Journal of Respiratory and Critical Care Medicine*, *158*(1), 126-132.

93. P Cadavid, A., L Bannenberg, G., C Arck, P., S Fitzgerald, J., & R Markert, U. (2011). Prevention and treatment of allergic asthma in pregnancy: from conventional drugs to new therapeutical approaches. *Current Pharmaceutical Biotechnology*, *12*(5), 758-764.

94. Kearney, D. M., & Lockey, R. F. (2006). Osteoporosis and asthma. *Annals of Allergy, Asthma & Immunology*, *96*(6), 769-776.

95. Farber, H. J., Capra, A. M., Finkelstein, J. A., Lozano, P., Quesenberry, C. P., Jensvold, N. G., ... & Lieu, T. A. (2003). Misunderstanding of asthma controller medications: association with nonadherence. *Journal of Asthma*, *40*(1), 17-25.

96. Sur, S., Wild, J. S., Choudhury, B. K., Sur, N., Alam, R., & Klinman, D. M. (1999). Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. *The Journal of Immunology*, *162*(10), 6284-6293.

97. Hansbro, N. G., Horvat, J. C., Wark, P. A., & Hansbro, P. M. (2008). Understanding the mechanisms of viral induced asthma: new therapeutic directions. *Pharmacology & therapeutics*, *117*(3), 313-353.

98. Akinbami, L. J., Moorman, J. E., Garbe, P. L., & Sondik, E. J. (2009). Status of childhood asthma in the United States, 1980–2007. *Pediatrics*, *123*(Supplement_3), S131-S145.

99. Gern, J. E. (2015). Virus/allergen interaction in asthma exacerbation. *Annals of the American Thoracic Society*, *12*(Supplement 2), S137-S143.

100. Peat, J. K. (1996). Prevention of asthma. *European Respiratory Journal*, *9*(7), 1545-1555.